Boston Scientific Launches New Irrigation Management System for Urology
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy BSX?
Source: PRnewswire
- FDA 510(k) Clearance: Boston Scientific announced that its Asurys™ Fluid Management System has received FDA 510(k) clearance, designed to provide irrigation and distention support during endoscopic urologic procedures, thereby enhancing surgical safety and effectiveness.
- Technological Innovation: The system can automatically regulate irrigation flow in real-time to maintain low intrarenal pressure (IRP), significantly reducing the risk of postoperative complications such as systemic inflammatory response syndrome (SIRS) and renal damage, thus improving patient recovery outcomes.
- Multifunctional Application: The Asurys System is applicable not only for ureteroscopy but also for cystoscopy, percutaneous nephrolithotomy (PCNL), and benign prostatic hyperplasia (BPH) procedures, broadening its market applicability and enhancing the company's competitiveness in the urology sector.
- Market Release Plan: The device is set for limited market release in the U.S. in the coming days, expected to advance kidney stone disease treatment by streamlining workflows and reducing the cognitive burden on endourologists.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BSX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BSX
Wall Street analysts forecast BSX stock price to rise
22 Analyst Rating
22 Buy
0 Hold
0 Sell
Strong Buy
Current: 70.170
Low
94.00
Averages
108.14
High
132.00
Current: 70.170
Low
94.00
Averages
108.14
High
132.00
About BSX
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Boston Scientific Launches New Irrigation Management System
- FDA 510(k) Clearance: Boston Scientific announced that its Asurys™ Fluid Management System has received FDA 510(k) clearance, designed to provide irrigation and distention support for endoscopic urologic procedures, marking a significant advancement in urology technology.
- Broad Clinical Applications: The system is applicable not only for ureteroscopy but also for cystoscopy, percutaneous nephrolithotomy (PCNL), and benign prostatic hyperplasia (BPH) procedures, which is expected to significantly enhance the safety and efficiency of these common surgeries.
- Real-Time Pressure Management: The Asurys System can monitor and adjust intrarenal pressure (IRP) in real-time, automatically regulating irrigation flow to minimize the risk of potential complications, thereby improving postoperative recovery outcomes and enhancing workflow efficiency for medical teams.
- Market Release Plans: The device is set for limited market release in the U.S. in the coming days, which is expected to lay the groundwork for Boston Scientific's further expansion in the urology market and drive ongoing innovation in medical technology.
See More
Boston Scientific Launches New Irrigation Management System for Urology
- FDA 510(k) Clearance: Boston Scientific announced that its Asurys™ Fluid Management System has received FDA 510(k) clearance, designed to provide irrigation and distention support during endoscopic urologic procedures, thereby enhancing surgical safety and effectiveness.
- Technological Innovation: The system can automatically regulate irrigation flow in real-time to maintain low intrarenal pressure (IRP), significantly reducing the risk of postoperative complications such as systemic inflammatory response syndrome (SIRS) and renal damage, thus improving patient recovery outcomes.
- Multifunctional Application: The Asurys System is applicable not only for ureteroscopy but also for cystoscopy, percutaneous nephrolithotomy (PCNL), and benign prostatic hyperplasia (BPH) procedures, broadening its market applicability and enhancing the company's competitiveness in the urology sector.
- Market Release Plan: The device is set for limited market release in the U.S. in the coming days, expected to advance kidney stone disease treatment by streamlining workflows and reducing the cognitive burden on endourologists.
See More
Boston Scientific Class Action Lawsuit Announcement
- Class Action Initiation: Boston Scientific faces a class action lawsuit for alleged violations of securities laws during stock transactions from July 23, 2025, to February 3, 2026, with investors required to apply as lead plaintiffs by May 4, 2026, highlighting significant legal risks for the company.
- Declining Financial Performance: On February 4, 2026, Boston Scientific reported fourth-quarter results showing a net income of $672 million and earnings per share of $0.45, which, despite year-over-year growth, fell short of the company's guidance range of $0.48 to $0.52, resulting in a stock price drop of over 17%.
- Market Share Erosion: The lawsuit alleges that Boston Scientific failed to disclose competitive pressures in the U.S. electrophysiology market, leading to a decline in market share and impacting the company's growth potential, indicating vulnerability in a competitive landscape.
- Legal Representation Process: Robbins Geller Rudman & Dowd LLP, as the primary legal representative, emphasizes that any investor who purchased Boston Scientific stock during the class period can seek lead plaintiff status, indicating that the legal challenges faced by the company may affect future investor confidence.
See More
Boston Scientific Faces Class Action Lawsuit Over Securities Violations
- Lawsuit Background: Boston Scientific Corporation is facing a class action lawsuit for alleged violations of federal securities laws, with plaintiffs being investors who purchased the company's securities between July 23, 2025, and February 3, 2026, seeking to recover damages.
- False Statement Allegations: The complaint alleges that executives made materially false and misleading statements during this period, failing to disclose that the growth rate of its U.S. electrophysiology segment was unsustainable, leading investors to misunderstand the company's prospects.
- Market Reaction: The lawsuit highlights that the company is experiencing adverse trends affecting procedure volumes, increasing competitive pressures, and regulatory hurdles, indicating that the growth inflection point for the electrophysiology segment occurred earlier than the market anticipated, impacting investor confidence.
- Investor Rights Protection: The law firm representing the plaintiffs offers legal services on a contingency fee basis, meaning they will only charge fees if successful, ensuring that investors do not incur additional costs in the lawsuit.
See More
Faruqi & Faruqi Encourages Boston Scientific Investors to Reach Out
- Legal Action Reminder: Faruq & Faruqi, LLP is investigating potential claims against Boston Scientific Corporation, specifically targeting investors who purchased or acquired the company's securities between July 23, 2025, and February 3, 2026, highlighting the legal risks they may face.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing contact numbers 877-247-4292 and 212-983-9330 (Ext. 1310) to discuss their legal rights and options.
- Class Action Deadline: Investors should note that the deadline to seek the role of lead plaintiff in the federal securities class action against Boston Scientific is May 4, 2026, making this timeline critical for potential claims.
- Law Firm Background: Faruq & Faruqi, LLP is a leading national securities law firm focused on providing legal support to investors, ensuring their rights are protected in the securities market.
See More
Boston Scientific Reports Positive EKOS System Clinical Trial Results
- Clinical Trial Success: Boston Scientific's HI-PEITHO global randomized trial demonstrated that the EKOS Endovascular System combined with anticoagulation met the composite primary endpoint, proving superior to the current standard of care for acute pulmonary embolism treatment.
- Significant Treatment Effects: The study revealed that the EKOS system effectively improves treatment outcomes for intermediate-risk pulmonary embolism patients by delivering a low dose of clot-dissolving medication directly to the clot and utilizing ultrasound energy to enhance medication dispersion, thereby reducing cardiovascular mortality.
- Guideline Updates Expected: Current medical guidelines recommend anticoagulation for all risk levels of pulmonary embolism, and the successful application of the EKOS system may prompt updates to these guidelines, facilitating broader clinical adoption.
- Market Potential: Given that pulmonary embolism is the third leading cause of cardiovascular mortality, the clinical success of the EKOS system not only opens new market opportunities for Boston Scientific but could also significantly enhance its market share in the cardiovascular sector.
See More
Boston Scientific Launches New Irrigation Management System
- FDA 510(k) Clearance: Boston Scientific announced that its Asurys™ Fluid Management System has received FDA 510(k) clearance, designed to provide irrigation and distention support for endoscopic urologic procedures, marking a significant advancement in urology technology.
- Broad Clinical Applications: The system is applicable not only for ureteroscopy but also for cystoscopy, percutaneous nephrolithotomy (PCNL), and benign prostatic hyperplasia (BPH) procedures, which is expected to significantly enhance the safety and efficiency of these common surgeries.
- Real-Time Pressure Management: The Asurys System can monitor and adjust intrarenal pressure (IRP) in real-time, automatically regulating irrigation flow to minimize the risk of potential complications, thereby improving postoperative recovery outcomes and enhancing workflow efficiency for medical teams.
- Market Release Plans: The device is set for limited market release in the U.S. in the coming days, which is expected to lay the groundwork for Boston Scientific's further expansion in the urology market and drive ongoing innovation in medical technology.
See More
Boston Scientific Launches New Irrigation Management System for Urology
- FDA 510(k) Clearance: Boston Scientific announced that its Asurys™ Fluid Management System has received FDA 510(k) clearance, designed to provide irrigation and distention support during endoscopic urologic procedures, thereby enhancing surgical safety and effectiveness.
- Technological Innovation: The system can automatically regulate irrigation flow in real-time to maintain low intrarenal pressure (IRP), significantly reducing the risk of postoperative complications such as systemic inflammatory response syndrome (SIRS) and renal damage, thus improving patient recovery outcomes.
- Multifunctional Application: The Asurys System is applicable not only for ureteroscopy but also for cystoscopy, percutaneous nephrolithotomy (PCNL), and benign prostatic hyperplasia (BPH) procedures, broadening its market applicability and enhancing the company's competitiveness in the urology sector.
- Market Release Plan: The device is set for limited market release in the U.S. in the coming days, expected to advance kidney stone disease treatment by streamlining workflows and reducing the cognitive burden on endourologists.
See More
Boston Scientific Class Action Lawsuit Announcement
- Class Action Initiation: Boston Scientific faces a class action lawsuit for alleged violations of securities laws during stock transactions from July 23, 2025, to February 3, 2026, with investors required to apply as lead plaintiffs by May 4, 2026, highlighting significant legal risks for the company.
- Declining Financial Performance: On February 4, 2026, Boston Scientific reported fourth-quarter results showing a net income of $672 million and earnings per share of $0.45, which, despite year-over-year growth, fell short of the company's guidance range of $0.48 to $0.52, resulting in a stock price drop of over 17%.
- Market Share Erosion: The lawsuit alleges that Boston Scientific failed to disclose competitive pressures in the U.S. electrophysiology market, leading to a decline in market share and impacting the company's growth potential, indicating vulnerability in a competitive landscape.
- Legal Representation Process: Robbins Geller Rudman & Dowd LLP, as the primary legal representative, emphasizes that any investor who purchased Boston Scientific stock during the class period can seek lead plaintiff status, indicating that the legal challenges faced by the company may affect future investor confidence.
See More
Boston Scientific Faces Class Action Lawsuit Over Securities Violations
- Lawsuit Background: Boston Scientific Corporation is facing a class action lawsuit for alleged violations of federal securities laws, with plaintiffs being investors who purchased the company's securities between July 23, 2025, and February 3, 2026, seeking to recover damages.
- False Statement Allegations: The complaint alleges that executives made materially false and misleading statements during this period, failing to disclose that the growth rate of its U.S. electrophysiology segment was unsustainable, leading investors to misunderstand the company's prospects.
- Market Reaction: The lawsuit highlights that the company is experiencing adverse trends affecting procedure volumes, increasing competitive pressures, and regulatory hurdles, indicating that the growth inflection point for the electrophysiology segment occurred earlier than the market anticipated, impacting investor confidence.
- Investor Rights Protection: The law firm representing the plaintiffs offers legal services on a contingency fee basis, meaning they will only charge fees if successful, ensuring that investors do not incur additional costs in the lawsuit.
See More
Faruqi & Faruqi Encourages Boston Scientific Investors to Reach Out
- Legal Action Reminder: Faruq & Faruqi, LLP is investigating potential claims against Boston Scientific Corporation, specifically targeting investors who purchased or acquired the company's securities between July 23, 2025, and February 3, 2026, highlighting the legal risks they may face.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing contact numbers 877-247-4292 and 212-983-9330 (Ext. 1310) to discuss their legal rights and options.
- Class Action Deadline: Investors should note that the deadline to seek the role of lead plaintiff in the federal securities class action against Boston Scientific is May 4, 2026, making this timeline critical for potential claims.
- Law Firm Background: Faruq & Faruqi, LLP is a leading national securities law firm focused on providing legal support to investors, ensuring their rights are protected in the securities market.
See More
Boston Scientific Reports Positive EKOS System Clinical Trial Results
- Clinical Trial Success: Boston Scientific's HI-PEITHO global randomized trial demonstrated that the EKOS Endovascular System combined with anticoagulation met the composite primary endpoint, proving superior to the current standard of care for acute pulmonary embolism treatment.
- Significant Treatment Effects: The study revealed that the EKOS system effectively improves treatment outcomes for intermediate-risk pulmonary embolism patients by delivering a low dose of clot-dissolving medication directly to the clot and utilizing ultrasound energy to enhance medication dispersion, thereby reducing cardiovascular mortality.
- Guideline Updates Expected: Current medical guidelines recommend anticoagulation for all risk levels of pulmonary embolism, and the successful application of the EKOS system may prompt updates to these guidelines, facilitating broader clinical adoption.
- Market Potential: Given that pulmonary embolism is the third leading cause of cardiovascular mortality, the clinical success of the EKOS system not only opens new market opportunities for Boston Scientific but could also significantly enhance its market share in the cardiovascular sector.
See More
